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Abstract. We present an argumentation model to explain the optimal treatment
plans recommended by a Satisfiability Modulo Theories solver for multimorbid
patients. The resulting framework can be queried to obtain supporting reasons
for nodes on a path following a model of argumentation schemes. The modelling
approach is generic and can be used for justifying similar sequences.
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1 Introduction
Multimorbidity, the presence of two or more chronic conditions in a person, is a ma-
jor healthcare concern across the globe. In the UK, NICE3 publishes evidence-based
recommendations for treatment, called Clinical Pathways, to formalise treatment prac-
tices. However, these pathways are based on evidence from single health conditions and
rarely consider the presence of comorbidities. Hence, treating multimorbidity involves
managing adverse interactions between several drugs corresponding to different condi-
tions. Several efficient approaches have been developed based on Satisfiability Modulo
Theories (SMT) solvers [2] to identify safe treatment plans. Medical practitioners are,
however, naturally reluctant to use automatic recommendations if they do not under-
stand the underlying reasoning. In this work, we combine the optimising efficiency of
SMT solvers with an argumentation framework for explaining their recommendations.
While the role of argumentation has been investigated in healthcare [4], explanations
in healthcare [8] and multimorbidity [3], the contribution of this paper is a novel ap-
proach for modelling graphs and their explanations using argumentation in the context
of multimorbidity. The SMT solver provides an optimal solution indicating the safest
medical treatment plan for multimorbidity. A set of argumentation schemes captures
reasons for these medical treatments as well as possible inconsistencies between rec-
ommended plans. We then show how critical questions can be used to query an argu-
mentation framework, where an agent can provide interactive explanations to a medical
practitioner. In this paper, we present the argumentation framework and its underlying
schemes which can be used in a multi-agent system to uncover explanations of recom-
mended paths.
3 For details see https://www.nice.org.uk
2 Argumentation and Multimorbidity for NICE Pathways
Clinical pathways are generic flowchart representations. They include guidelines for
drug treatments of specific conditions as well as other best practices. We refer to them
as NICE pathways in this work. Kovalov and Bowles [5] use the SMT solver Z3 [7] to
find the safest path across multiple NICE pathways such that adverse drug interactions
between all the NICE pathways under consideration are minimised. SMT solvers solve
Boolean Satisfiability problems by finding a truth assignment modulo theories and its
optimal assignment for some defined objective function. Three types of adverse inter-
actions are considered in [5]: between drugs, between a drug and a disease, and patient
intolerance for specific drugs. The approach is scalable to any number of drug alterna-
tives and finds the optimal solution minimising conflicts according to given criteria as
opposed to an all or nothing approach. While the solver captures the NICE pathways
quantitatively to indicate progression to the next stage of treatment, as a black-box
model it does not provide the underlying qualitative intuition. In this paper, our focus is
the encoding of this qualitative information in the solver’s output.
We adopt the formal representation of [2, 5] to represent Pharmaceutical Graphs
(PG) which capture the original ordering and branching structure of the NICE pathway
in terms of the recommended drug or drug groups. A PG is a directed acyclic graph
with a root note for a disease, and where every other node in the graph is associated
with a drug or a drug group. For patients with multimorbidities, several event structures
are used to model the NICE pathways of each of the conditions they have. A path in the
graph represents a complete treatment plan for a single disease, and a combination of
paths across diseases is extracted in [5] via an objective function on the basis of a total
score for Z3. This score is a combination of medicine efficacy (positive score) and drug
interaction conflict (negative score) permitting to identify the optimal treatment plan.
Our definition of PG is based on that of [2], formally considering the unfolding
of a PG as an event structure where events are associated with a drug or a group and
different treatment options are captured by conflicting events.
Definition 1. An event structure is a triple E = (Ev,→∗,#) where Ev is a set of events
and →∗,# ∈ Ev×Ev are binary relations called causality and conflict, respectively.
Causality →∗ is a partial order. Conflict # is symmetric and irreflexive, and propa-
gates over causality, i.e.,(e#e′∧ e′→∗ e′′)⇒ e#e′′ for all e,e′,e′′ ∈ Ev. Two events are
concurrent, written e ‖ e′, iff ¬(e→∗ e′∨ e′→∗ e∨ e#e′).
Here we consider PG as the graph formed by the causality relationships of E such
that PG = (Ev,→∗), and our starting representation of a PG is correspondent to the
representation of Z3 input as event structure. We refer to a trace of execution on PG as
a sequence of events Ppath = 〈e0; . . . ;en〉, Ppath⊆ PG, where for each ei,e j ∈ Ev there
exists a causal relation (ei→∗ e j) ∈→∗. Hence the output from Z3 is a set of paths for
each disease optimising a goal over all sets of event structures under consideration.
In order to compute justifications for this path, we define an argumentation model
using a simpler version of ASPIC+ [6] without preferences, strict rules and undercuts.
An argumentation framework AF is formed by arguments A and attacks→: A ×A .
An argument A∈A is constructed from a knowledge base K ⊆L where L is a propo-
sitional logic language, and defeasible rules R. A ∈A is a premise in K or a derivation
of a conclusion from rules and premises in K. Argument A1 attacks A2, A1→ A2, if
the conclusion of A1 is contrary to a premise (undermines) or to a conclusion (rebuts)
of A2 determined by a contrariness function ¯: L → 2L . The sets of acceptable argu-
ments (i.e., extensions ξ ) in an AF is computed according to the preferred semantics. A
model of argumentation schemes, stereotypical patterns of reasoning, defines premises,
conclusions and critical questions [10]. Schemes are used to derive grounded defeasible
rules ki ∈R [6]. In our work, attacks will be derived through ASPIC+, while critical
questions are used to explore arguments within an extension. L contains the set of
propositions Props in turn divided into subsets Ti ⊂ Props. A lower case letter refers
to a proposition type ti ∈Ti and we refer to grounded propositions with upper case let-
ters. An argument scheme is defined as Argγ : t0, . . . , t j⇒ tn where γ is the name of the
scheme and ti ∈Ti from which we can derive a rule kγ : P0, . . . ,Pj⇒ Pn, kγ ∈R.
3 Argumentation Model
In our model, we adapt PG, input to Z3, for adding explanations and convert it into its
equivalent argument representation. Next, we apply a knowledge engineering process
to extract the explanations from NICE pathways that were left out by the SMT solver.
Lastly, we link the explanations to the respective PG nodes in our final model.
Convert Pharmaceutical Graph to PGraph. Starting from a PG, the event structure
representation presented in Section 2, we define a PGraph as a graph extension of PG.
PGraph differentiates from its parent PG by having the graph structure marked explic-
itly in terms of branches required for explanation modelling. A PGraph = (Ev,→∗)
augments the set of events with a new set of nodes where Sb or StartBranch is a set of
events marking the start of a branch, Eb or EndBranch marks the end of a branch. To
represent drug groups as sub-branches in PG, we consider a set of nodes Dg or Drug-
Group named after the drug group which marks the start of the sub-branch. Similarly
we have a set of nodes Eg or EndGroup to mark the end of the sub-branch. Causality
relationships link the new nodes to their respective branches. A path on a PG is then
mapped to a path on PGraph by accounting for additional marking nodes. In Fig. 1 we
show an example of PG = (Ev,→∗) for Diabetes from [5] and its correspondent ex-
tension PGraph. The root node represents the disease (Diabetes), while the remaining
nodes represent recommended drugs or drug groups. For example, the node Sulfony-
lurea indicates that seven drugs belong to this group.
Modelling Paths in the Argumentation Model. A casual relation e→∗ e′ in PGraph
is represented using a Transition Argument Scheme. Transition arguments accumulate
the path from start to the current transition using a linear argument structure.
Definition 2. A Transition Argument Scheme is ArgT = {Given e in a PGraph, e′ fol-
lows from e} where e→∗ e′ ∈ PGraph.
This scheme can be represented as ArgT : e⇒ e′, where e,e′ ∈ TEv are propositions
of type event and TEv contains all events Ev of PGraph. An inference rule derived
through ArgT can be written as kT1 : E1⇒ E2 with kTi ∈R. A single critical question
Fig. 1. PG to PGraph conversion for Diabetes.
is defined: CQT – Is there a transition to e? The question undermines the argument on
its premise with ¬e, and other arguments of type ArgT can be used to respond.
In order to model different paths taken along PGraph as alternative solutions, here
we introduce a negation to represent alternatives such that for all concurrent events
e′,e′′ ∈ Ev, e′ ‖ e′′ we have e′ ∈ ē′′,e′′ ∈ ē′.
Structured Explanation for Clinical Pathways. We base the explanations of the rec-
ommended paths on the drug information provided by NICE. We assess the practical
value of this content by talks with experts. Then we manually filter out relevant infor-
mation and organise it into different levels and types.
Level: The choice of a node in a graph involves decisions at different abstraction
levels. For example, starting from the initial node, the medical practitioner needs to
choose a branch. Next, they decide which node to transition to and why. This is im-
portant because in the treatment plans, moving to the next node in the graph indicates
that the previous treatment is no longer effective, so it is discouraged. Once made, the
transition as well as the choice of drug or drug group needs to be justified. Hence, the
abstraction levels represent different types of decisions to be made. Higher levels of
abstraction act as filters for lower levels. As the choice of a node moves from higher to
lower level, explanations become more specific and adapt to the user’s need for detail.
For example, a non-expert might be satisfied with a high-level explanation but a more
expert user might press for more specific reasons encoded in the lower levels.
We identify four levels of abstraction for PGraph (cf. Fig. 1): a Branch contains
Nodes where a Node can be a Drug or a composite Group, composed of Drug nodes.
1. Branch Level: Given a PGraph, the first decision is to choose between alternative
branches. This level justifies a transition to a specific branch.
Reasons TReas Maps to TType TLevel
R1 it is indicated for age less than 55 years IP BRANCH
R2 it is the default treatment on the recommended pathway IP BRANCH
R3 it is indicated in next stage of treatment if review of previous treatment does not work IP NODE
R4 it is contraindicated in CD DRUG
R5 it adversely reacts with suggested drug DD DRUG
Fig. 2. Type hierarchy for Treatment, Interactions and Side Effects with examples for Diabetes.
2. Node Level: This level allows reasoning about why a transition is taken irrespective
of the destination node. In the context of multimorbidity, these reasons allow talking
about transitions into the next stage of treatment.
3. Drug Level: Reasons about the destination node, i.e. a drug or a drug group.
4. Group Level: Reasons about relationships between drugs in a drug family.
In order to identify what level of explanation a reason is attributed to, we define specific
propositions in our language TLevel = {BRANCH,NODE,DRUG,GROUP} ⊂ Props.
Type: We classify the reasons for choosing or not choosing a drug into four types
based on the content. These are distributed across different levels: 1) Clinical pathway;
2) Treatment; 3) Interactions; and 4) Side Effects. The Clinical Pathway type allows the
PGraph structure itself to be used as justification for a drug choice. Figure 2 shows the
sub-classification within the remaining types with those used in this work highlighted
in bold. As above, a set of dedicated propositions are used to identify the different type
of reason: TType = {IP,CD,CP,DD,PGraph} ⊂ Props.
Reason: represents the explanation text and is associated with a Level and a Type. A
reason is identified with a proposition type ri ∈ TReas ⊂ Props. The table in Fig. 2 pro-
vides some examples of reasons indicating the proposition type, level and a description.
Argument Schemes for Explanations. The Explain Argument Scheme models expla-
nations based on the reasons, types and levels and shows a support or counter reason
for giving a drug represented as event e.
Definition 3. An Explain Argument Scheme ArgE , is such that given a reason r ∈TReas
with attributes t ∈TType and l ∈TLevel for event e in PGraph, it follows that there is a
justification for prescribing e.
We customize the generic ArgE to model different types of supporting explana-
tions that can highlight adverse interactions between events in the PGraph. We specify
additional elements as follows in order to define these schemes. We assume TDis =
{d|d is a disease name}, TCond = {c|c is a medical condition expressing patient state},
TExp ={explaine|explaine is a proposition representing an explanation for a drug/drug
group e ∈ TEv} and TDis,TCond ,TExp ⊂ Props. The general argument scheme is pre-
sented as ArgE : r, t, l⇒ explaine. Four types of schemes ArgE are defined on the basis
of the type of reason: ArgEIP mentions a justification for a treatment; ArgEDD indicates
that a drug e1 is prescribed as another drug e2 reacting with e1 has not been prescribed;
ArgECD indicates that e cannot be taken in case of a disease s ∈ TDis but the disease is
not present; and ArgECP includes information on whether e can or cannot be taken in
presence or absence of another condition c ∈TCond .
Reasons from ArgE do not aggregate. A drug can be prescribed as long as there is a
single surviving ArgE to justify it. Explain arguments allow a critical question such as:
CQE – Is there an alternative combination of r, t, l for there being a justification for e?
This rebuts the conclusion with ¬explaine, and can be answered with another ArgE .
Linking the Two Models. The Give Argument Scheme links graph and explanations:
Definition 4. ArgG = {Given an event e in PGraph and an explanation explaine ∈
TExp in favour of e, it follows that e can be prescribed}.
In order to define formally this scheme, we use TPres = {givee|givee is a proposition
expressing prescription of e ∈ TEv}. A Give argument scheme is then formulated as
ArgG : e,explaine ⇒ givee where givee ∈ TPres. Two critical questions are defined for
this scheme: CQG1 – Is there a transition to e?; and CQG2 – Is there an explanation
for e?. Both CQs challenge the premises: CQG1 (same as CQT ) with ¬e and and CQG2
with ¬explaine which can be responded with ArgT and ArgE , respectively.
General Argumentation Model. So far, we have outlined a number of argumenta-
tion schemes to derive defeasible rules R. The knowledge base is defined as K ⊆
TDis ∪TCond ∪TLevel ∪TType ∪TReas ∪TEv where TEv represents a subset of negated
drug/drug group events, s.t. ¬e ∈TEv,e ∈TEv. The components of K are identified as:
(i) for qi ∈ (TDis∪TCond ∪TEv), we assert qi ∈ K based on NICE pathways, reflecting
the domain properties, which will constitute premises for Explain Arguments; (ii) for
qi ∈ (TLevel ∪TType ∪TReas), we assert qi ∈ K as part of the modelling permitting an
administrator to tune the explanations returned by the system. R and K form the basis
for an AF to explain an event structure representing a NICE treatment pathway.
Asserting the disease node in the graph activates the graph through the linear struc-
ture of Transition arguments. At this point we can derive a set of preferred extensions ξ
from the argumentation system as described in Section 2. A preferred extension is then
ξi = {AT1 , . . . ,ATn ,AE1 , . . . ,AEk ,AG1 , . . . ,AGm} where ATi ∈A are arguments about the
treatment path, AEi ∈ A are justifications for prescribing the treatment, AGi ∈ A are
treatments that can be justifiably prescribed. Hence, ξi maps an SMT solver output
Ppath = 〈e0; . . . ;en〉 and additionally incorporates corresponding explanations.
Transition arguments rebut other Transition arguments and undermine correspond-
ing Give and Explain arguments on their Transition premises. Consequently, Give ar-
guments can be undermined on their Transition premise directly and indirectly by un-
dermining one of the premises of their Explain arguments.
Example of Argumentation Model. Here we show part of the ASPIC+ model for the
Diabetes PGraph from Fig. 1. The adverse interactions modelled in this example are
only for demonstrative purposes. The example can be extended to include multiple dis-
ease PGraphs and their explanations by adding corresponding premises, rules and con-
trariness definitions. The resulting extensions will then include combinations of paths
across all graphs, representing the safest path in the context of multimorbidity.
We now show how the AF can be used by an agent to justify prescribed drugs. As-
suming the SMT solver gives the optimal path as branch 1 of Diabetes PGraph in Fig. 1.
We map this to Ppath = 〈Diabetes;StartBD1; Metformin;Pioglitazone;EndBD1〉 and
get the corresponding preferred extension ξ1 ={A60,A54,A56,A57, .. }. Figure 3 shows
the attacks in the resulting argument graph for this extension along with a subset of the
relevant argument mappings. The arguments included in the extension are highlighted
in grey. Assume the agent proposes to give Pioglitazone, A60. A user can ask for justi-
fications using some of the critical questions. The agent responds with an argument that
can resolve the challenge. For example, if the user asks for a justification about the tran-
sition to Pioglitazone, CQG1, the agent can respond with Because there is a transition to
Pioglitazone from Metformin, via argument A54. If the user asks about an explanation
for this drug, CQG2, the agent can respond with A56: Because it is indicated for age less
than 55 years (R1). The agent can move A57, Because it is indicated in the next stage of
treatment if a review of previous treatment does not work (R3), in response to a request
for alternative explanations to the drug, CQE1.
4 Conclusion and Future Work
We presented an argumentation model to justify the choices on a clinical pathway, as
identified by the SMT solver for multimorbid patients. While the solver only encoded
drug information in the optimal path, our system delivers additional information ex-
tracted from the NICE pathways as well as other sources that justifies each event in the
path. Our approach can generalise to explanations of similar graph structures.
A recent approach has integrated argumentation with the Transition-based Medi-
cal Recommendation (TMR) model to represent guidelines and their interactions [3].
While they use argumentation for reasoning, we present a novel approach to show how
argumentation can add interpretability to a black-box model such as a SMT solver. Al-
though significant work has been invested in making machine learning models more
transparent [1], the same focus on making SMT solvers transparent has lacked so far.
The explanations from our model can be used as the basis of an agent dialogue pro-
tocol which provides justifications to the user in an interactive way [9], similar to the
approach of [8]. Possible future directions include conducting usability studies to see
how useful are the generated explanations and formulating the content of the explana-
tions on data collected from patients and medical practitioners.
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